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Abstract Macroscopic vascular invasion (macroVI) is associated with poor outcomes after liver transplantation (LT) for
hepatocellular carcinoma (HCC). Whether microvascular invasion (microVI) is associated with the same adverse prognosis
is unclear. One hundred and fifty-five consecutive patients with confirmed HCC after LT from March 1991 to 2004 at our
institution were reviewed. Patients had to satisfy Milan criteria to be accepted for LT. They were followed with surveillance
images every 3 months while on the waiting list. Disease-free survival (DFS) and overall survival (OS) were evaluated by
Kaplan–Meier analysis. Demographic, tumor, and histopathologic characteristics were tested for their prognostic
significance. Median follow-up after LT was 30 months. Overall graft survival rates were 87, 74, and 65% at 1, 3, and
5 years, respectively. All recurrences (22/155, 14%) developed within 4 years after LT with an overall 5-year DFS of 79%.
Vascular invasion, either microVI or macroVI, was more likely in patients with multicentric HCC (n≥3, p<0.001) and
larger tumor size >4 cm (p=0.04). Tumor size >5 cm (p=0.04), advanced pathological TMN stage (p=0.007), microVI (p=
0.001), and macroVI (p<0.001) predicted poor tumor-free survival on univariate analysis, but only macroVI was significant
in multivariate analysis (hazard ratio 54.2, 95% confidence interval 11, 266). Furthermore, only macroVI was a significant
predictor of mortality after LT (p=0.01). Macrovascular invasion is strongly associated with high rates of recurrence and
diminished survival after LT whereas microVI is not an independent risk factor.
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Introduction
In 1996, Mazzaferro et al.
1 documented excellent survival
results after liver transplantation (LT) in a highly selected
group of patients with hepatocellular carcinoma (HCC)
with a single tumor <5 cm or as many as three tumors, each
smaller than 3 cm. Recent studies have shown that selected
patients who do not meet these criteria can still be cured
with a transplant; the challenge now is to decide which
factors, other than size and number, carry a sufficiently
poor prognosis to deny transplantation.
2–5
Gross vascular invasion or radiological evidence of
tumor invasion in major veins is a known determinant of
poor outcome after resection or transplantation for HCC
and is an absolute contraindication to LT.
4–13 Macro-
vascular invasion (macroVI) or gross vascular invasion of
major portal or hepatic veins evident visually at time of
transplant or on pathological evaluation may also be a
predictor of recurrence after LT.
14 Whether microvascular
invasion (microVI), defined as microscopic tumor invasion
in smaller intrahepatic vessels identified on pathologic
analysis, or macroVI should also be considered a contrain-
dication to LT is controversial. Both types of tumor
invasion are difficult to determine pre-LT; therefore, their
significance remains uncertain.
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factors, namely, poorly differentiated grade, microVI, and
macroVI, to be independent predictors of poor survival
after LT.
4,11,15–17 We have previously shown that microVI
is an independent predictor of early recurrence after
resection for HCC.
5 The purpose of this study was to
determine if microVI, macroVI, and other pathological
factors are associated with tumor recurrence after LT and
examine the outcomes thereafter. If these factors are
predictors of poor tumor-free survival, then how can we
attempt to identify these variables before transplant?
Patients and Methods
One hundred fifty-nine consecutive patients with confirmed
HCC on liver explant pathology after LT from October
1991 to October 2004 at our institution were reviewed from
a prospective database. The cohort includes 32 patients
(20%) with incidental tumors. Patients had to satisfy Milan
criteria and have no radiologic evidence of gross vascular
invasion to be accepted for LT. Four patients were omitted
from analysis for recurrent hepatitis B virus (HBV) before
antiviral therapy; after 1991, hepatitis B immune globulin,
lamivudine, or combination therapy was used. Patients with
known HCC were followed every 3 months while on the
waiting list with either an ultrasound or triphasic computed
tomography (CT). Patients with HCC were eligible for
deceased donor whole organs (n=149) and split (n=0) or
living donor LT (n=6).
Patient, tumor, operative, and treatment characteristics
were evaluated using a prospective clinical database and
review of all pathological explants. The stage, size, and
histopathology of the tumor were determined by analysis of
the liver explant. Patients were staged based on the
explanted specimens using the TNM staging classification
of the American Liver Tumor Study Group
18. Tumor size
was measured as the largest diameter of the major tumor in
centimeters. MacroVI was defined as gross vascular
invasion into major portal vessels or hepatic veins
identified either intraoperatively or on pathologic explant,
whereas microVI was determined on pathologic analysis as
microscopic vascular invasion of small vessels within the
parenchyma of the liver. Pretransplant therapy was used in
selective cases; if waiting time was determined to be longer
than 6 months, patients commonly underwent radio
frequency ablation as a bridge to LT. This was performed
in an attempt to keep patients within Milan criteria while on
the LT waiting list. Postoperative immunosuppression was
similar in all patients and consisted of cyclosporine or
tacrolimus and steroids.
After LT, patients were followed with Q3 monthly alpha-
fetoprotein (AFP) and CT along with standard post-LT
evaluation. Recurrences were defined as new nodules
diagnosed by CT with confirmed biopsy in most cases.
Overall survival (OS) was death as a result of any cause
after LT. Patients were followed until death or study closure
(arbitrarily denoted as October 1, 2004). Data was collected
until May 1, 2005 to ensure at least 6 months of follow-up
for all patients.
Statistical Package for Social Sciences software (SPSS,
Inc., Chicago, IL) was used for data analysis. Statistical
comparison of categorical and continuous variables was
performed using the χ
2 test and Mann–Whitney U test,
respectively. All data was reported as median with range,
mean ± SD or interquartile range (IQR) when appropriate.
Analysis of patient OS and disease-free survival (DFS) was
performed according to the Kaplan–Meier method. Patient
survival in different groups was compared using the log-
rank test. All variables with a p value less than 0.1 were
then included in a multivariate analysis applying the Cox
multiple backward stepwise model.
Results
Patient Characteristics
Of the 1,070 LTs performed during the 13-year period from
1991 to 2004, 159 patients (14%) had HCC. After omission
of 4 patients because of recurrent HBV before the antiviral
therapy era, 155 patients were included in this analysis
(Table 1). The average waiting time for LT was 7 months.
There was no perioperative mortality. The median age was
57 years (range 28–70) and the majority of patients were
men (79%). The median age of all patients who underwent
LT for any cause was 51 years (range 16–71). The most
common causes of end-stage liver disease and HCC were
hepatitis C virus (HCV) (n=79; 51%), alcoholic liver
disease (n=34; 22%), and HBV (n=25; 16%). Selected
patients underwent pre-LT therapy, most commonly radio
frequency or percutaneous ethanol ablation (ablation, 23%),
but the majority of patients received no treatment before LT
(72%). Use of ablation did not result in any adverse
outcomes in this series of patients who underwent eventual
LT.
Histopathological Analysis
The pathologic features for the 155 explants are shown in
Table 2. The median number of tumors was 2 (range 1–20)
and 18% were bilobar. The median size of the largest tumor
was 2.6 cm and most tumors were graded as well or
moderately differentiated (74%). Gross macroVI was
evident in 3.9% (6/155) of the explants on pathologic
examination, whereas 21% (33/155) of explants had the
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fication, 31 patients (20%) had stage I tumors, 69 patients
(44%) had stage II tumors, 26 patients had stage III tumors
(17%), and 29 patients had stage IV tumors (19%). Patterns
of advanced stage were most often because of multifocal
HCC or three or greater in number (40%).
Vascular invasion was associated with both the number
and size of tumors. Liver explants, with either microVI or
macroVI, had more tumors (3.8 vs 2.0, p<0.001) and were
larger in size (3.6 cm vs 2.8 cm, p=0.04) compared to those
without vascular invasion. Specifically, if microVI or
macroVI was present on histopathology, 64 and 100% of
the tumors, respectively, were outside of the Milan criteria
or were TNM stage III or IV. Histological grade was not
associated with either type of vascular invasion; 85% of
patients with either type of vascular invasion had favorably
differentiated tumors. Ablation did not affect the rate of
vascular invasion, either microVI or macroVI, in this series.
Eleven of 33 patients (33%) with vascular invasion on
explant analysis had undergone ablation of their tumor.
Predictors of Recurrence and Survival
The 5-year disease-specific survival was 79% (Fig. 1a). All
recurrences developed within 44 months after LT. The 1-,
3-, and 5-year overall graft OS rates were 87, 74, and 65%,
respectively (Fig. 1b). Only 22 patients (14%) developed
tumor recurrence after LT with a median follow-up of
30 months (range 6–144 months). Eighty-six percent of
patients (122/155) are currently alive and free of cancer.
There was no difference in OS in patients with incidental
tumors compared to those with known HCC (data not
shown), but a significant difference was observed in DFS
(5-year OS rate 94 vs 74%, p=0.02).
The median time to recurrence for the 22 patients who
developed recurrent HCC was 16.3 months (IQR 8.0–28).
Tumor size >5 cm (p=0.04), pathological TMN stage (p=
0.007), microVI (p=0.001), and macroVI (p<0.001) were
found to be independent predictors of tumor-free survival.
Patients with tumor size of 5 cm or larger had a 5-year DFS
of 48 vs 82% for those with tumors smaller than 5 cm.
Advanced TMN stage was also associated with poor
recurrence-free survival after LT (Fig. 2). Twenty-one of
the 22 patients (95%) who developed HCC recurrence were
found to have either microVI (n=15) or macroVI (n=6) on
pathological analysis. This accounts for 68% (15/22) of all
patients with microVI and 100% (6/6) of patients with
macroVI in the entire study. Patients with macroVI had a
median DFS of only 7.1 months compared to a more
favorable DFS in patients with microVI or no vascular
invasion (median not achieved) (Fig. 3). No significant
differences in DFS based on age, sex type, hepatitis status,
tumor grade, bilobar disease, tumor number, ablative
therapy, or type of transplant were found on univariate
analysis. Pre-LT therapy did not result in any improvement
in DFS or OS after LT (data not shown).
In a multivariate analysis including factors with an
influence on DFS, only macroVI (hazard ratio [HR] 54.2,
95% CI 11.03–266.4) was identified to be predictive
(Table 2). This was confirmed with a Cox backward
stepwise model of multivariate analysis (data not shown).
Discussion
In this study, we report our experience with LT for HCC
with a specific focus on pathological factors affecting long-
term outcomes. Overall survival rates of LT for HCC were
87, 74, and 65% at 1, 3, and 5 years, respectively, with a
median follow-up time of 30 months. The overall recur-
rence rate was 14% with 79% 5-year disease-specific
survival. Patients with incidental tumors had similar OS
rates as those with known tumors consistent with previous
reports,
8,9,14,15,19 but in this study, a significant difference
was found in DFS. Our studies suggest that large tumor size
(>4 cm) and multiple tumors (≥3) correlate with an increased
incidence of vascular invasion and may provide a surrogate
marker for entities that are often difficult to detect before LT.
Recurrence rates after LT may not simply reflect only
size and number as suggested in the initial Milan series, but
may be a complex interplay of host- and tumor-related
Table 1 Pretransplant Demographics of 155 Patients with HCC Who
Underwent LT
Pretransplant Criteria N=155 p Value
Median age (range) 57 (28–70) 0.48
Sex 0.38
Male 123 (79%)
Female 32 (21%)
Cause of liver disease 0.10
HCV 79 (51%)
HBV 25 (16%)
Alcohol 34 (22%)
Cryptogenic 7 (4.5%)
Alpha-1 antitrypsin 6 (3.9%)
NASH 2 (1.3%)
PBC 2 (1.3%)
Pretransplant therapy 0.67
Ablation 36 (23%)
Resection 6 (3.9%)
TACE 1 (0.6%)
EBRT 1 (0.6%)
None 111 (72%)
The p values were determined by log-rank test as predictor of DFS
after Kaplan–Meier analysis.
NASH = nonalcoholic steatohepatitis, PBC = primary biliary cirrhosis,
EBRT = external beam radiation therapy
466 J Gastrointest Surg (2007) 11:464–471factors, which are still largely unknown.
20 This report
suggests that tumor grade, size, number, and microVI do not
influence outcome after LT for HCC; only the presence of
macroVI appears to be associated with poor outcomes on
multivariate analysis. MacroVI and microVI were more
commonly found in multicentric (three or more) and large
(>4 cm) HCC. Furthermore, 21 of 22 recurrences had
evidence of either microVI or macroVI on pathologic
examination. Because we are unable to identify these
biologic factors preoperatively, markers of histopathologic
or biologic variables that predict poor outcomes are
extremely important.
14,20–22
MacroVI was shown to be an independent predictor
of tumor recurrence after LT in some studies.
4,9,10,14
The Pittsburgh group found that microVI and major
vascular invasion was associated with increased risk of
recurrence by multivariate analysis.
4,8 In a report of 344
patients with HCC treated by LT, microVI and macroVI
were associated with 4.4- and 15-fold increased risk of
recurrence, respectively.
8 Shetty et al.
14 found that
macroVI, but not microVI, was a significant predictor of
DSF and OS after LT for HCC. In this study, microVI is
associated with higher stage and recurrent tumors, but
does not appear to be an independent factor for survival.
The role of microVI on posttransplant recurrence and
survival outcomes for HCC still remains unclear. Several
published studies have found poorly differentiated histo-
logical grade or microVI to be independent predictors of
impaired survival after LT.
11,15–17 Jonas et al.
11 found
vascular invasion and histological grade to be the only
statistically significant independent predictors of poor
survival after LT in 120 patients. In their study, only
poorly differentiated tumors larger than 5 cm predicted the
presence of microVI. But other studies involving LT and
HCC were not able to corroborate poor results regarding
microVI.
3,14,23,24 The close relationship between histo-
logical grade and microVI may explain why microVI is
often eliminated in multivariate models for analyzing
tumor recurrence prognostic factors that include histolog-
ical grading and vice versa.
4,8,11,15,23,25,26 Multiple
tumors, larger tumors, and higher grade of differentiation
have all been shown to be associated with microVI after
resection for HCC. Esnaola et al.
13 reported that tumor size
greater than 4 cm and poorly differentiated/undifferentiat-
ed histopathologic grade increased the odds of microVI by
3 and 6.3-fold, respectively, but these tumors were
primarily in Child class A cirrhotic.
The degree of fibrosis and scarring of the liver may play
a significant role in the biological behavior and significance
of microVI and macroVI. We have previously shown that
microVI was a significant predictor of early recurrence and
death after resection for HCC in cirrhotic patients.
5 Most
recurrences were intrahepatic and away from the staple line,
suggesting that liver mobilization and manipulation may
cause progression of microVI or a new tumor has dev-
eloped in the presence of ongoing oncogenic stimulus from
cirrhosis. For these reasons, prognostic factors for LT from
resection studies should be interpreted with caution and a
possible rationale why microVI is so important after
resection but not after LT.
12,13 Lack of manipulation of
the liver and intrahepatic dissection may be a potential
explanation for the lack of importance of microVI with LT.
Because of the importance of histological features of
HCC, some have advocated pre-LT biopsy to examine grade,
vascular invasion, and genetic typing.
13,15,20 Complications
of needle biopsy such as tumor tract seeding and lack of
sensitivity have made routine biopsy unfavorable.
27 In our
experience, needle biopsy was a poor predictor of microVI
Table 2 Pathologic Characteristics of 155 Liver Explants
Characteristic N=155 p Value HR (95% CI)
No. of tumors
Median (range, cm) 2 (1–20) 0.23
<3 126 (81%)
>3 29 (19%)
Bilobar 32 (21%) 0.15
Size
Median (range; cm) 2.6 (.1–16) 0.04 0.47 (0.14,1.61)
<5 cm 145 (94%)
>5 cm 15 (10%)
Stage
I 31 (20%) 0.007 1.17 (0.39,3.50)
II 69 (44%)
III 26 (17%)
IV 29 (19%)
Positive lymph nodes 3 (2.0%) 0.31
Vascular invasion
a
Microscopic 33 (21%) 0.001 3.16 (0.92,10.93)
Macroscopic 6 (4%) <0.001 54.2 (11.03,266.4)
None 121 (78%)
b 1.0
c
Grade
Well/mod 115 (74%) 0.36
Poor 13 (9%)
N/A
d 27 (17%)
Margins
Positive 2 (1%) 0.25
Negative 153 (99%)
Incidental tumor 34 (22%) 0.19
The p values were determined by chi-square test or log-rank test of
variables after Kaplan–Meier analysis (univariate). HR (95% CI)
represents multivariate analysis of factors affecting recurrence after
resection.
aFive of six patients had characteristics of both microvascular and
macrovascular tumor invasion.
bReference category for comparison
cReference category for each categorical variable is assigned HR=1.0.
dNot available in the analysis
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Figure 1 (A) Disease-free sur-
vival after LT for HCC of 155
patients. (B) Overall graft sur-
vival after LT for HCC of 155
patients.
468 J Gastrointest Surg (2007) 11:464–471or macroVI, and therefore was not considered in our pre-LT
work-up for HCC (data not shown).
There are several limitations to this study and therefore
some of the results should be interpreted with caution. The
need to standardize grading systems for HCC has long been
recognized and would allow us to determine if tumor grade
is indeed an important prognostic marker for recurrence and
survival. Few tumors in this study were graded as poorly
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J Gastrointest Surg (2007) 11:464–471 469differentiated; moreover, in 27 patients, their grade was not
determined. Results from histopathological analysis are
often met with inherent biases from the pathologist and
comprehensive evaluation of the whole liver explant may
vary among pathologists and institutions. Finally, with very
few tumors containing macroVI, strong conclusions about
prognostic characteristics concerning macroVI cannot be
made in this report. Whether microVI is a harbinger of
macroVI or in some way correlated with a more aggressive
form of HCC remains unclear.
The use of pathological and biological features of the
tumor may allow us to identify those patients who are at
increased risk of recurrence; then these patients should be
considered for adjuvant therapy before evidence of a
recurrence. Because vascular invasion is more common in
multicentric (>3) HCC or large tumors (>4 cm), we propose
shortening the interval of pre-LT imaging in patients with
these tumors to identify vascular invasion or rapid growth of
the tumor before LT. Genetic testing of tumors before LT
may be a novel method to predict other prognostic factors
affecting recurrence.
20 Several studies have reported im-
proved posttransplant survival in HCC patients with trans-
catheter arterial chemoembolization (TACE) or systemic
therapy,
28–31 but overall results for adjuvant chemotherapy
post-LT were disappointing.
32 Because of small numbers,
this would be best done in a multicenter-randomized trial.
We are currently evaluating the role of tumor size and
number in our allocation system in LT for HCC to determine
their respective predictive value for prognosis.
Insummary,LTforHCCcanbeperformedwithacceptable
survival outcomes. A single tumor characteristic alone does
not appear to determine prognosis or outcome. In the present
study,macroVIalonewasassociatedwithverypooroutcomes
after LT. Extending criteria of LT for advanced HCC is
possibleonlywithbetterpatientselectionusingimprovedpre-
LT staging and identification of histopathological biological
markers such as macroVI that would preclude LT.
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